Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00314860




Registration number
NCT00314860
Ethics application status
Date submitted
13/04/2006
Date registered
17/04/2006
Date last updated
18/10/2016

Titles & IDs
Public title
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
Scientific title
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Secondary ID [1] 0 0
101468/204
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Restless Legs Syndrome 0 0
Restless Legs Syndrome (RLS) 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Anxiety
Mental Health 0 0 0 0
Other mental health disorders
Neurological 0 0 0 0
Other neurological disorders
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ropinirole Extended Release (XR)

Treatment: Drugs: ropinirole Extended Release (XR)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To demonstrate the superior tolerability of ropinirole extended release compared to ropinirole immediate release in adult subjects with RLS requiring evening and night-time coverage of RLS symptoms
Timepoint [1] 0 0
12 Weeks
Secondary outcome [1] 0 0
To compare the safety profile and to evaluate the clinical benefits (as assessed by efficacy endpoints and patient-reported outcomes) of ropinirole extended release compared to ropinirole immediate release in subjects with RLS.
Timepoint [1] 0 0
12 Weeks

Eligibility
Key inclusion criteria
- Diagnosis of primary RLS according to RLS Diagnostic Clinical Interview and
International Restless Legs Syndrome Study Group Diagnostic Criteria.

- Disturbed sleep, with both evening (between 5:00 pm and 8:00 pm) and night time
(between 8:00 pm and 8:00 am) symptoms requiring treatment.
Minimum age
18 Years
Maximum age
79 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

- Signs of secondary RLS.

- Primary sleep disorder or movement disorder other than RLS.

- Unstable medical conditions.

- Inability to tolerate dopamine agonists or dopamine antagonists.

- Unwilling to discontinue any medications currently being taken to treat RLS symptoms.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2006
Sample size
Target
Accrual to date
Final
568
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
GSK Investigational Site - Camperdown
Recruitment hospital [2] 0 0
GSK Investigational Site - Auchenflower
Recruitment hospital [3] 0 0
GSK Investigational Site - Kippa Ring
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
4066 - Auchenflower
Recruitment postcode(s) [3] 0 0
4021 - Kippa Ring
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Idaho
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
Nevada
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
North Dakota
Country [14] 0 0
United States of America
State/province [14] 0 0
Oklahoma
Country [15] 0 0
United States of America
State/province [15] 0 0
Rhode Island
Country [16] 0 0
United States of America
State/province [16] 0 0
Vermont
Country [17] 0 0
Austria
State/province [17] 0 0
Innsbruck
Country [18] 0 0
Austria
State/province [18] 0 0
Vienna
Country [19] 0 0
Belgium
State/province [19] 0 0
Brussels
Country [20] 0 0
Belgium
State/province [20] 0 0
Charleroi
Country [21] 0 0
Belgium
State/province [21] 0 0
Edegem
Country [22] 0 0
Belgium
State/province [22] 0 0
Liege
Country [23] 0 0
Belgium
State/province [23] 0 0
Liège
Country [24] 0 0
Denmark
State/province [24] 0 0
Glostrup
Country [25] 0 0
Denmark
State/province [25] 0 0
Hvidovre
Country [26] 0 0
Denmark
State/province [26] 0 0
Koebenhavn NV
Country [27] 0 0
Denmark
State/province [27] 0 0
Odense C
Country [28] 0 0
France
State/province [28] 0 0
Anzin
Country [29] 0 0
France
State/province [29] 0 0
Bordeaux
Country [30] 0 0
France
State/province [30] 0 0
Bron Cedex
Country [31] 0 0
France
State/province [31] 0 0
Créteil
Country [32] 0 0
France
State/province [32] 0 0
Grenoble Cedex 09
Country [33] 0 0
France
State/province [33] 0 0
Lille
Country [34] 0 0
France
State/province [34] 0 0
Montbrison
Country [35] 0 0
France
State/province [35] 0 0
Nancy Cedex
Country [36] 0 0
France
State/province [36] 0 0
Pessac Cedex
Country [37] 0 0
Germany
State/province [37] 0 0
Bayern
Country [38] 0 0
Germany
State/province [38] 0 0
Mecklenburg-Vorpommern
Country [39] 0 0
Germany
State/province [39] 0 0
Sachsen-Anhalt
Country [40] 0 0
Germany
State/province [40] 0 0
Sachsen
Country [41] 0 0
Germany
State/province [41] 0 0
Thueringen
Country [42] 0 0
Germany
State/province [42] 0 0
Berlin
Country [43] 0 0
Italy
State/province [43] 0 0
Emilia-Romagna
Country [44] 0 0
Italy
State/province [44] 0 0
Lazio
Country [45] 0 0
Italy
State/province [45] 0 0
Lombardia
Country [46] 0 0
Italy
State/province [46] 0 0
Toscana
Country [47] 0 0
Netherlands
State/province [47] 0 0
Amsterdam
Country [48] 0 0
Netherlands
State/province [48] 0 0
Geldermalsen
Country [49] 0 0
Netherlands
State/province [49] 0 0
Grubbenvorst
Country [50] 0 0
Netherlands
State/province [50] 0 0
Hoogwoud
Country [51] 0 0
Netherlands
State/province [51] 0 0
Nieuwegein
Country [52] 0 0
Netherlands
State/province [52] 0 0
Roelofarendsveen
Country [53] 0 0
Netherlands
State/province [53] 0 0
Zwolle
Country [54] 0 0
Norway
State/province [54] 0 0
Bergen
Country [55] 0 0
Norway
State/province [55] 0 0
Oslo
Country [56] 0 0
Norway
State/province [56] 0 0
Sandvika
Country [57] 0 0
Spain
State/province [57] 0 0
Barcelona
Country [58] 0 0
Spain
State/province [58] 0 0
Granada
Country [59] 0 0
Spain
State/province [59] 0 0
Madrid
Country [60] 0 0
Spain
State/province [60] 0 0
Palma de Mallorca
Country [61] 0 0
Spain
State/province [61] 0 0
San Sebastián
Country [62] 0 0
Spain
State/province [62] 0 0
Zaragoza
Country [63] 0 0
Sweden
State/province [63] 0 0
Göteborg
Country [64] 0 0
Sweden
State/province [64] 0 0
Helsingborg
Country [65] 0 0
Sweden
State/province [65] 0 0
Örebro
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Derbyshire
Country [67] 0 0
United Kingdom
State/province [67] 0 0
Lancashire
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Somerset
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Warwickshire
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Wiltshire
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Corsham
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Doncaster
Country [73] 0 0
United Kingdom
State/province [73] 0 0
Ledbury

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Restless Legs Syndrome (RLS) study in adults comparing immediate release ropinirole with
extended release ropinirole over 12 weeks
Trial website
https://clinicaltrials.gov/ct2/show/NCT00314860
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00314860